August 23, 2016 03:43 PM EDT

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

John Carroll

Editor & Founder

Clovis Oncology stock $CLVS shot up 30% Tuesday afternoon after the biotech laid out competitive pivotal data for its PARP inhibitor rucaparib, which has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

A look at biotech's year of the megaround

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Clo­vis soars as its PARP drug ru­ca­parib lines up for FDA re­view with pos­i­tive da­ta

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

A look at biotech's year of the megaround

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes